정양삼한의원

논문 정양삼

> paper > 정양삼

경신해지환(GGT1)이 형질전환 비만모델 hGHTg 수컷 쥐의 비만 관련 유전자 발현에 미치는 영향

서론

輕身解脂丸 (GGT1)이 형질전환 비만모델 hGHTg 수컷 쥐의 비만관련 유전자 발현에 미치는 영향

정양삼 · 윤미정¹ · 김경철² · 신순식*

Effects of GyeongshinhaeGihwan 1(GGT1) on the Expression of Obesity-related Genes in Obese Male hGHTg Rats

Yang Sam Jung, Michung Yoon¹ , Gyeong Cheol Kim² , Soon Shik Shin*

To investigate whether GyeongshinhaeGihwan 1(GGT1), an anti-obesity herbal medicine widely used in oriental medicine, regulates the expression of obesity-related genes, we measured the changes in mRNA levels of these genes by GGT1 in human growth hormone transgenic (hGHTg) obese male rats, and these effects by GGT1 were compared with those of reductil (RD), an anti-obesity drug approved by FDA. Rats received once daily oral administrations of autoclaved water, RD, or GGT1 for 8 weeks. At the end of study, rats were sacrificed and tissues were harvested. Total RNA from adipose tissue, liver and kidney was prepared and the mRNA levels for LPL (lipoprotein lipase), PPARγ (peroxisome proliferator activated receptor-gamma), PPARδ (peroxisome proliferator activated receptor-delta), leptin, TNFα (tumor necrosis factor-alpha), and internal standard G3PDH (glyceraldehyde-3- phosphate dehydrogenase) were analyzed by RT-PCR. PPARγ mRNA levels of liver and kidney were decreased in drug-treated groups compared with control group and the decrease of PPARγ expression was more prominent in GGT1 group than in RD group, suggesting that GGT1 is effective in the inhibition of adipogenesis and lipid storage by decreasing the PPARγ expression. In contrast, PPARδ mRNA levels of adipose tissue and kidney were increased by RD and GGT1, and the magnitudes of increase were higher in GGT1 group than in RD group, indicating that GGT1 stimulates fatty acid oxidation and energy metabolism by activating PPARδ expression. Compared with control and RD groups, GGT1 group had higher concentrations of serum leptin, a well-known inhibitor of appetite. However, The mRNA levels of leptin, LPL, and TNFα were not changed by GGT1 and RD, compared with DW. These results demonstrate that GGT1 not only decreases PPARγ expression of liver and kidney, but also increases PPARδ expression of adipose tissue and kidney, leading to the regulation of obesity and that these effects were more pronounced in GGT1 group compared with RD group. In addition, GGT1 seems to prevent obesity by increasing the serum leptin levels.

Key words : GyeongshinhaeGihwan 1(GGT1), leptin, male hGHTg, obesity-related gene, PPARδ, PPARγ, reductil

서론

輕身解脂丸 (GyeongshinhaeGihwan ¹ , GGT1)은 太陰人의 調理肺元湯1)加減方으로 임상에서 항비만제로 다수 활용되고 있다.

그럼에도 불구하고 이 輕身解脂丸의 작용기전에 대한 연구는 미흡한 실정이다.

비만은 에너지섭취와 에너지소비의 불균형으로 에너지섭취가 에너지소비보다 클때 일어난다. 여기에는 음식섭취, 물질대사, 열생성이 비만유발에 중요한 지표로서 관련되어 있고, 특히 이들을 조절하는데 관련된 유전자가 많은 역할을 하는 것으로 알려져 있다. 항비만효과를 입증하는 방법 중의 하나는 비만유전자 발현을 측정하여 알아내는 법이다²).

본 연구에서는 형질전환 비만모델 hGHTg (human growth hormone transgenic) 수컷 쥐를 이용하여 GGT1의 항비만효과가 어느 비만유전자와 관련되어 있는지를 알아보고, 또한 norepinephrine과 serotonin의 재흡수를 억제하는 작용을 하여 항비만효과를 나타내는 약물로서 미국 FDA에서 승인된 reductil (리덕틸, RD)과는 어떤 차별된 효과가 있는지를 검증하고자 하였다.